Absstract of: US2024261503A1
A method of insulin delivery, the method may include obtaining one or more blood glucose readings of a user, and, based on the blood glucose readings, generating a set of insulin delivery actions that may include delivery of a baseline basal rate or predefined variations of the baseline basal rate. The method may also include monitoring previous insulin delivery actions to the user to determine whether the previous insulin delivery actions include insulin beyond a threshold amount, where the previous insulin delivery actions may include delivery of the baseline basal rate or predefined variations of the baseline basal rate, and, based on the previous insulin delivery actions including insulin beyond the threshold amount, adjusting the set of insulin delivery actions.
Absstract of: US2024261502A1
A processor-implemented method for controlling delivery of insulin to a user of an insulin infusion device involves: obtaining user status sensor data indicative of a sleeping status of a user of an insulin infusion device, and controlling operation of the insulin infusion device in accordance with the sleeping status of the user.
Absstract of: US2024260839A1
An apparatus, system, and method for monitoring a person suffering from a chronic medical condition predicts and assesses physiological changes which could affect the care of that subject. Examples of such chronic diseases include (but are not limited to) heart failure, chronic obstructive pulmonary disease, asthma, and diabetes. Monitoring includes measurements of respiratory movements, which can then be analyzed for evidence of changes in respiratory rate, or for events such as hypopneas, apneas and periodic breathing. Monitoring may be augmented by the measurement of nocturnal heart rate in conjunction with respiratory monitoring. Additional physiological measurements can also be taken such as subjective symptom data, blood pressure, blood oxygen levels, and various molecular markers. Embodiments for detection of respiratory patterns and heart rate are disclosed, together with exemplar implementations of decision processes based on these measurements.
Absstract of: WO2024160808A1
The present disclosure relates to highly integrated sensor devices such as implantable devices, continuous monitoring devices and portable smart devices for determining a physiological parameter in a bodily fluid and/or tissue of a subject. Further, the present disclosure relates to methods for determining a physiological parameter in a bodily fluid and/or tissue of a subject.
Absstract of: WO2024163950A2
Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. Each microneedle of the microneedle array may include a microneedle body, an electrode material on the microneedle body, a biorecognition layer on the electrode material, a diffusion-limiting layer on the biorecognition layer, an interferent blocking agent, and/or an attachment enhancer between the biorecognition layer and the diffusion-limiting layer, where the interferent blocking agent and the attachment enhancer are configured to improve sensor sensitivity variability.
Absstract of: EP4410197A1
The present invention relates to a method for predicting a biometric value in a blood glucose measurement system and, more particularly, to a biometric value prediction method capable of predicting a future biometric value of a user by generating a predictive model through a communication terminal having a small memory and amount of calculations, such as a smartphone that the user always carries to manage a biometric value, and applying the biometric value of the user to the generated predictive model, and capable of predicting a future biometric value of the user without requiring biometric information of other nearby users and without access to a server, by generating a predictive model personalized for the user on the basis of biometric history information of the user.
Absstract of: EP4410200A2
The present disclosure relates to a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device is produced in a state in which a body attachment unit has been assembled inside an applicator, so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body only by simply activating the applicator. Particularly, the present invention provides a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device: includes a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use thereof, without additional work for connecting a separate transmitter, and easier maintenance; and is activated by a user's operation after the body attachment unit is attached to the body, so as to enable the operation start time to be adjusted to an appropriate time according to user's needs, and to enable the operation to start in a stabilized state so that blood glucose can be measured more accurately.
Absstract of: WO2024158159A1
Disclosed is a device and method for improving blood sugar control ability using electrical stimulation. The present invention comprises: a pair of pads attached to the skin in the form of a patch or tape coated with adhesive conductive hydrogel to be attached to the upper and lower circumferences of the abdomen; and a control module which outputs a control signal so that the pads operate at a set microcurrent and a set frequency within a set operating time. The microcurrent is configured to be set in 50 ㎂ increments in the range of 200-400 ㎂, the frequency is configured to be set in 10 Hz increments in the range of 1-60 Hz, and the set time is configured to be set in 10-minute increments in the range of 10 minutes-2 hours, thus having the effect of lowering fasting blood sugar or improving blood sugar control ability through electrical stimulation in case of impaired glucose tolerance or impaired fasting glucose.
Absstract of: US2024252073A1
The present disclosure relates to a method for calibrating non-invasive biometric information measured by a non-invasive biometric information measurement apparatus, and more specifically to a method for calibrating non-invasive biometric information, wherein non-invasive biometric information measured by a non-invasive blood glucose meter can be learned using continuous biometric information measured by a continuous blood glucose meter, and thereby calibrated so as to be personalized to a user, and by using the continuous biometric information, measured by the continuous blood glucose meter to calibrate uncertain non-invasive biometric information measured by the non-invasive blood glucose meter so as to be personalized to the user, the pattern of increase/decrease in user biometric information can be accurately determined from the still uncertain non-invasive biometric information.
Absstract of: US2024252115A1
Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. The microneedle array may include, for example, at least one microneedle including a tapered distal portion having an insulated distal apex, and an electrode on a surface of the tapered distal portion located proximal to the insulated distal apex. At least some of the microneedles may be electrically isolated such that one or more electrodes is individually addressable.
Absstract of: US2024252076A1
Method and apparatus for optimizing analyte sensor calibration including receiving a current blood glucose measurement, retrieving a time information for an upcoming scheduled calibration event for calibrating an analyte sensor, determining temporal proximity between the current blood glucose measurement and the retrieved time information for the upcoming calibration event, initiating a calibration routine to calibrate the analyte sensor when the determined temporal proximity is within a predetermined time period, and overriding the upcoming scheduled calibration event using the current blood glucose measurement are provided.
Absstract of: US2024252753A1
Disclosed are a device, system, methods and computer-readable medium products that provide an updated insulin-to-carbohydrate ratio and an updated total daily insulin. The described processes may be used for periodic updating of the insulin-to-carbohydrate ratio and the total daily insulin. The insulin-to-carbohydrate ratio and/or the total may be used in the calculation of new doses of insulin that a drug delivery device may be commanded to deliver to a user.
Absstract of: US2024252748A1
A system for selectively supplying a substance to a person, for regulating the concentration of glucose in the blood of a person, includes a device for selectively supplying a substance which includes a port for connecting to a transport element, and a controller for controlling the device, an infusion set including an infusion element comprising a first connector for connecting to a second connector of the transport element, and a transport element including second and third connectors. The following parts of the system can form at least one pair: the infusion elements; the second connectors; second connector with said or a respective third connector; or combinations thereof. The device can detect and/or be inputted with information indicating the pair is formed, and the controller controls the device such that a priming function can only be performed if detected and/or inputted that said at least one pair is formed.
Absstract of: US2024252751A1
A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and/or a detected location of the user.
Absstract of: US2024252741A1
A user-wearable patch pump system for delivery of insulin or other medicament can include a patch pump having a reusable drive unit and a replaceable and refillable cartridge. The cartridge can selectively attach to and be detached from the drive unit. The cartridge can initially be inserted onto the drive unit in a first orientation at an angle to the drive unit and then be rotated to align the cartridge with the drive unit and lock the cartridge in place on the drive unit to form the patch pump.
Absstract of: US2024257965A1
Disclosed herein are techniques for delivery of diabetes therapy. In some embodiments, the techniques may involve receiving, using one or more processors of an insulin pump, gesture data indicative of a gesture of a patient using the insulin pump. The techniques may further involve determining, by the one or more processors of the insulin pump and based on a connection to a short-range communication system of a vehicle, that the patient is in the vehicle and determining, based at least in part on the gesture data, that the patient is operating the vehicle. The techniques may further involve determining, using the one or more processors of the insulin pump, a driving therapy protocol based on the determination that the patient is operating the vehicle.
Absstract of: US2024257392A1
A fall prevention system that monitors the real-time pose of a user and provides alerts in response to a determination that the user may be likely to fall. To accurately determine whether the user is in an unstable pose, the fall prevention system receives video images of the user (and, in some instances, depth information) captured by multiple image capture systems from multiple angles. To process multiple video streams with sufficient speed to provide alerts in near real-time, the fall prevention system uses a pose estimation and stability evaluation process that is optimized to reduce computational expense. For example, the fall prevention process may be realized by a local controller (e.g., worn by the user) that receives video images via a local connection and processes those images locally using pre-trained machine learning models that are uniquely capable of quickly capturing and evaluating the pose of the user.
Absstract of: US2024252068A1
A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values. The sensors' distal portions may be inserted into a user's body via a single delivery needle and may be co-located inside the user's body.
Absstract of: US2024252069A1
In one aspect, a method of estimating an HbA1c level is provided. The method may include obtaining a first and second glucose measurement, adding the first and the second glucose measurements to a glucose measurement data set, and calculating an estimated HbA1c level using at least the glucose measurement data set. In another aspect, a method of calculating a range of an estimated HbA1c level is provided. The method may comprise at least calculating an estimated HbA1c level and a standard deviation of the estimated HbA1c level using a glucose measurement data set, and combining the estimated HbA1c level with the standard deviation of the estimated HbA1c level to acquire the range of the estimated HbA1c level. In another aspect, a glucose monitoring device may display glycemic variability of an individual.
Absstract of: AU2024204775A1
Systems, devices, and methods are provided for the control of interfacing between applications that facilitate the monitoring of diabetes running on a mobile device, including the authentication of a third party user interface application by a sensor interface application. Control of the display of current analyte levels and critical events is also provided.
Absstract of: US2024252067A1
Systems and methods for displaying metrics related to a user are described. Data indicative of glucose levels of the user is received. A first alert point for a potential glucose episode in a data set of time correlated glucose data, e.g., a glucose vs. time curve, is identified if the last received glucose data point satisfies at least one alert condition. A first potential local minimum in a first time period is identified. The first potential local minimum is confirmed as a first start point of a first glucose episode if the first potential local minimum satisfies at least one local minimum condition. An integrated area under the curve over time of a first portion of the graph beginning at the first start point of the first glucose episode to the first alert point is calculated. A first count value is assigned to the first portion.
Absstract of: CA3232846A1
A device for delivering fluid and an inserter in a device for delivering fluid, the device comprising an annular guide configured to engage a pen or a syringe injection needle, a main body enclosed by a base and a cover, and an inserter for expelling the fluid, wherein the inserter includes a glucose monitoring sensor disposed coaxially with the inserter. The inserter comprising a cannula configured to deliver the fluid, and a glucose monitoring sensor disposed coaxially to and surrounding the cannula, wherein the glucose monitoring sensor includes a biosensor layer that monitors glucose in the fluid and provides feedback to the device.
Absstract of: MX2021008767A
The invention relates to a device (1) comprising a measuring unit (2) with a measuring module (4) for measuring the glucose level, a first computer module (5) for processing data from a first part of the process for measuring the glucose level, a first communications module (6), a first data storage module (7) and a pushbutton (8). The device also comprises a personal monitoring unit (3) with second and third communication modules (17, 20), a second computer module (18) for processing data from a second part of the process for measuring the glucose level, an interface module (19) and a second data storage module (22). Also described is a method for non-invasive blood glucose level estimation.
Absstract of: EP4406568A2
A fluid delivery device comprising a fluid reservoir; a transcutaneous access tool fluidly coupled to the fluid reservoir, the transcutaneous access tool including a needle or a trocar; and a transcutaneous access tool insertion mechanism for deploying the transcutaneous access tool, wherein the insertion mechanism is configured to insert and retract the needle/trocar in a single, uninterrupted motion. In certain embodiments, the fluid delivery device may comprise an infusion device comprising a fluid reservoir for containing a therapeutic fluid; and a transcutaneous access tool fluidly coupled to the fluid reservoir for delivering the therapeutic fluid subcutaneously and for introducing a monitoring test strip subcutaneously, and methods of use thereof.
Nº publicación: EP4405969A1 31/07/2024
Applicant:
NESTLE SA [CH]
Soci\u00E9t\u00E9 des Produits Nestl\u00E9 S.A
Absstract of: CN117941007A
Methods and systems for monitoring risk and recommending dietary intake for prediabetes via a personalized digital platform are disclosed. The method may include generating an application for assessing a user-specific prediabetic risk, wherein the application prompts an input of a user attribute to assess the user-specific prediabetic risk; receiving a user attribute of the user from the user device to evaluate a user-specific prediabetes risk for the user; generating a feature vector associated with the user based on the vectorization of the user attributes; performing clustering of a plurality of feature vectors including a plurality of reference feature vectors and a feature vector associated with the user; determining a prediabetic risk level of the user based on the cluster; and generating a recommendation for diet intake for the user based on the prediabetic risk level of the user and the user attributes.